All News
Tofacitinib Shows Promise in Alopecia, Eczema and Vitiligo
Tofacitinib has been approved for use in rheumatoid arthritis.
Read ArticleJuvenile Dermatomyositis Responds Best to Methotrexate and Prednisone
Lancet reports the results of a randomized controlled trial comparing prednisone alone to prednisone combined with either methotrexate (MTX) or cyclosporine (CyA) in new-onset juvenile dermatomyositis (JDM).
Read Article
The Rising Price of Dermatologic Drugs
Containment of health care costs was a primary goal of the Patient Protection and Affordable Care Act. But there is little evidence of success in curbing the rising price of prescription drugs. As such, many medications are unaffordable to those who need them.
Read Article
Chronic Digital Ulcers in Systemic Sclerosis Portends More Complications
A prospective, international observational study of systemic sclerosis patients enrolled in the Digital Ulcers Outcome (DUO) Registry: Patients were required to have ≥3 follow-up visits over at least a 2 year observation period between 2008-2013.
Read Article
Eczema May Respond to Tofacitinib
A recent report from the Journal of the American Academy of Dermatology found that the oral Janus kinase (JAK) inhibitor tofacitinib to be effective in the treatment of moderate to severe atopic dermatitis.
Read Article
From Psoriasis to PsA: Who and Why?
The number of patients with psoriasis who go on to develop psoriatic arthritis (PsA) is considerably higher than has previously been estimated, a prospective cohort study found.
Read Article
Repeat Skin Cancer Risk with Methotrexate and Biologics
Using Medicare claims data, a retrospective cohort study analyzed the risk of a second non-melanomatous skin cancer (NMSC) in 9460 individuals (6841 with RA and 2788 with IBD).
Read Article
High Level Skin Responses Seen with Inhibitor of IL-23p19 in Psoriasis
Rheumatology News reports the results of a novel trial presented at the European Academy of Dermatology and Venereology meeting in Copenhagen.
Read Article
Brodalumab vs. Ustekinumab: Head-to-Head Studies of Psoriasis
AMAGINE-2 and AMAGINE-3 are in two phase 3 studies that compare multiple doses of brodalumab (anti-IL-17) and ustekinumab (anti-12/23) in adults with moderate-to-severe psoriasis.
Read Article
Ustekinumab Effective in Adolescents with Psoriasis
Biologic and new drug development seldom targets children and adolescents. This study evaluated the efficacy and safety of ustekinumab in adolescents age 12 to 17 years with moderate-to-severe psoriasis,
Read Article
TICOPA Study: Tight Control in Psoriatic Arthritis
Tight control in rheumatoid arthritis was introduced with the TICORA trial and validated in numerous treat-to-target studies since. Now the benefits of tight control in psoriatic arthritis (PsA) have been reported.
Read Article
Adalimumab FDA Approved for Hidradenitis Suppurativa
Abbvie announced on 9/10/15 that adalimumab (Humira) has been FDA approved for the treatment of moderate to severe hidradenitis suppurativa (HS) and is now the first and only FDA-approved therapy for adults with HS.
Read Article
VEGF121-Fibrin as a Potential Therapy for Skin Ulcers in Systemic Sclerosis
The etiology of systemic sclerosis (SSc) remains unclear, but appears to involve complex pathogenic interactions between the immune system, the vasculature and fibrotic processes.
Read Article
Secukinumab Bests Ustekinumab in Psoriasis CLEAR Study
The CLEAR study was a one-year, randomized, double-blind trial compared subcutaneous standard doses of secukinumab (anti-IL17) and ustekinumab (anti-IL12/23) in patients with moderate-severe plaque psoriasis.
Read Article
Priorities for NIAMS Research Funding
Dr. Steven Katz describes how NIAMS sets priorities for investing congressionally-appropriated funds.
Read Article
Psoriasis Patients Satisfied with Biologics
A recent study published in the journal Patient Preference and Adherence examined insured patients from the Optum Research Database who had moderate to severe plaque psoriasis and queried them about their satisfaction with therapy.
Read Article
International Psoriasis Council Publishes its Research Priorities
The British Journal of Dermatology has published online the results of an International Psoriasis Council (IPC) survey identifying 21 psoriasis research priorities. The results will also appear in a future print edition of the journal.
Read Article
AstraZeneca Pushes Forward on Brodalumab Development
Despite Amgen's withdrawal as a co-developer of brodalumab, the anti-IL17A monoclonal antibody, AstraZeneca has announced it will push its plan to develop the drug. Brodalumab is currently in phase III trials for use in psoriasis, psoriatic arthritis and ankylosing spondylitis.
Read Article
10 Year Study Identifies Predictors of Skin Progression in Systemic Sclerosis
The European Scleroderma Trials and Research (EUSTAR) cohort has reported the results of their prospective study to identify onset symptoms and risk factors for skin sclerosis and digital ulcers (DUs) in early onset systemic sclerosis (SSc) patients.
Read Article
Bidirectional Association Between Uveitis and Psoriatic Disease
A Danish population, claims-based study studied the the associations between 74,129 patients with incident psoriasis and 13,114 with incident uveitis between 1997 and 2011.
Read Article
